Alectinib (Alecensa®)

Assessment Status Rapid Review Complete
Drug Alectinib
Brand Alecensa®
Indication For the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib.
Assessment Process
Rapid review commissioned 03/01/2017
Rapid review completed 27/02/2017
Rapid review outcome Full pharmacoeconomic evaluation recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations October 2017.